{
  "id": "42_ref_0",
  "query": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。",
  "query_data": {
    "id": "42_ref_0",
    "original_id": 42,
    "refined_index": 0,
    "question": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。",
    "answer": "{'(1)': {'MW': 246.2, 'logP': -0.9, 'TPSA': 92.0, 'HBD': 3, 'HBA': 5, 'RB': 4, 'Lipinski_violations_eval_1': 0, 'Lipinski_violations_eval_2': 0, 'result_relation': '两次结果相同（均满足规则）'}, '(2)': {'optimization_method': 'ETKDG', 'force_field': 'MMFF', 'max_iterations': 500, 'converged': True, 'total_energy': '72.8 kcal/mol', 'Rg': 2.35, 'PMI': [120.4, 230.8, 350.9], 'asphericity': 0.24, 'eccentricity': 0.78}, '(3)': {'SAS_raw': 4.7, 'SAS_final_1dp': 4.7, 'source': '题面给定SAS_raw', 'range_check': '[1,10]内'}, '(4)': {'path_2D': '/images/Floxuridine_2D.png', 'path_3D': '/models/Floxuridine_3D.sdf', 'usage': '2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性'}, '(5)': {'summary_index': {'P1': '(1)中的理化性质与Lipinski评估结果', 'G1': '(2)中的几何优化与形状描述符', 'S1': '(3)中的最终SAS', 'Paths': '(4)中的2D/3D路径'}, 'cross_checks': ['SAS范围：S1∈[1,10]', 'Lipinski两次评估结果相同，均满足规则', '理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征'], 'overall_conclusion': '满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征'}}",
    "metadata": {
      "subject": "化学",
      "topic": "药物化学与合成可及性",
      "image_path": [],
      "solution_steps": [
        "【分子识别与解析】解析5-Fluorodeoxyuridine的SMILES字符串：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O",
        "【SAS计算】调用 calculate_synthetic_accessibility(smiles) 使用Ertl-Schuffenhauer算法计算合成可及性分数",
        "SAS基于分子复杂度、环系统、立体化学和已知合成片段进行统计评估",
        "获得SAS = 3.5，对应\"相对容易合成\"（2.0-4.0范围）",
        "【理化性质分析】调用 mol_basic_physicochemical_info(smiles) 获取完整的分子信息",
        "分子式：C9H11FN2O5，分子量：246.07 g/mol",
        "LogP = -1.68（亲水性强），TPSA = 104.55 Å²（极性表面积大）",
        "氢键供体：3，氢键受体：6，可旋转键：2",
        "芳香环：1（嘧啶环），总环数：2（嘧啶环+糖环）",
        "【Lipinski成药性评估】检查Lipinski五规则的违规情况",
        "✓ MW(246.07) ≤ 500，✓ LogP(-1.68) ≤ 5，✓ HBD(3) ≤ 5，✓ HBA(6) ≤ 10",
        "违规数 = 0，类药性 = ✓ 是",
        "【3D可视化】调用 chem_visualizer 生成2D结构图和3D投影图",
        "生成图像：5_Fluorodeoxyuridine_2d.png（平面结构）",
        "5_Fluorodeoxyuridine_3d_projection.png（3D投影）",
        "5_Fluorodeoxyuridine_3d_matplotlib.png（3D立体图）",
        "【3D结构优化】调用 optimize_geometry(smiles, method='ETKDGv3', force_field='MMFF', max_iters=200)",
        "初始能量：-0.55 kcal/mol → 优化后能量：-30.79 kcal/mol",
        "能量降低：ΔE = -30.24 kcal/mol（结构显著稳定化）",
        "【3D性质计算】调用 get_3d_properties(smiles, method='ETKDGv3', conf_id=0)",
        "主惯性矩：PMI1=496.58, PMI2=2099.67, PMI3=2215.85 amu·Ų",
        "归一化惯性矩比：NPR1=0.224, NPR2=0.948",
        "分子形状：极端棒状/纤维状（NPR1<0.5, NPR2>0.95）",
        "回转半径：Rg = 3.126 Å（分子尺寸的特征长度）",
        "非球形度：asphericity = 0.478（显著偏离球形）",
        "偏心率：eccentricity = 0.975（高度拉伸的椭球形）",
        "【合成难度评估】根据SAS=3.5给出合成难度评价",
        "合成难度：相对容易合成（★★☆☆☆）",
        "核苷类似物的典型复杂度，适合药物开发",
        "【药物应用背景】5-FdU是胸苷酸合成酶抑制剂，用于治疗结直肠癌和肝癌",
        "商品名：Floxuridine, FUDR",
        "作用机制：干扰DNA合成，诱导癌细胞凋亡",
        "【最终答案】合成可及性分数 SAS = 3.5"
      ],
      "tool_expected": [
        "calculate_synthetic_accessibility",
        "mol_basic_physicochemical_info",
        "chem_visualizer",
        "optimize_geometry",
        "get_3d_properties"
      ],
      "golden_answer": [
        {
          "(1)": {
            "MW": 246.2,
            "logP": -0.9,
            "TPSA": 92.0,
            "HBD": 3,
            "HBA": 5,
            "RB": 4,
            "Lipinski_violations_eval_1": 0,
            "Lipinski_violations_eval_2": 0,
            "result_relation": "两次结果相同（均满足规则）"
          },
          "(2)": {
            "optimization_method": "ETKDG",
            "force_field": "MMFF",
            "max_iterations": 500,
            "converged": true,
            "total_energy": "72.8 kcal/mol",
            "Rg": 2.35,
            "PMI": [
              120.4,
              230.8,
              350.9
            ],
            "asphericity": 0.24,
            "eccentricity": 0.78
          },
          "(3)": {
            "SAS_raw": 4.7,
            "SAS_final_1dp": 4.7,
            "source": "题面给定SAS_raw",
            "range_check": "[1,10]内"
          },
          "(4)": {
            "path_2D": "/images/Floxuridine_2D.png",
            "path_3D": "/models/Floxuridine_3D.sdf",
            "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
          },
          "(5)": {
            "summary_index": {
              "P1": "(1)中的理化性质与Lipinski评估结果",
              "G1": "(2)中的几何优化与形状描述符",
              "S1": "(3)中的最终SAS",
              "Paths": "(4)中的2D/3D路径"
            },
            "cross_checks": [
              "SAS范围：S1∈[1,10]",
              "Lipinski两次评估结果相同，均满足规则",
              "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
            ],
            "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
          }
        }
      ],
      "original_question_id": "42",
      "test_type": "refined"
    },
    "usage_tool_protocol": [
      {
        "type": "function",
        "function": {
          "name": "calculate_synthetic_accessibility",
          "description": "计算分子的合成可及性分数（Synthetic Accessibility Score, SAS）。基于Ertl-Schuffenhauer算法，评估有机分子的合成难度。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串，或化学名称（会自动转换）。例如: 'CCO'（乙醇）, 'CC(=O)Oc1ccccc1C(=O)O'（阿司匹林）, 'aspirin'"
              }
            },
            "required": [
              "smiles"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_analyzer.py",
          "return_type": "float",
          "return_range": "1.0-10.0",
          "return_interpretation": "1.0=非常容易合成, 2.0-4.0=相对容易, 4.0-6.0=中等难度, 6.0-8.0=较难, 8.0-10.0=非常难",
          "algorithm": "Ertl & Schuffenhauer (2009) - 基于分子复杂度和片段贡献",
          "reference": "Journal of Cheminformatics, 1(1), 8"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "mol_basic_physicochemical_info",
          "description": "计算分子的基本理化性质和类药性评估。提供分子的基本信息、物化性质和Lipinski五规则评估。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串，或化学名称（会自动转换）。例如: 'CCO', 'CC(=O)Oc1ccccc1C(=O)O', 'aspirin'"
              }
            },
            "required": [
              "smiles"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_analyzer.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "chem_visualizer",
          "description": "分子可视化工具，支持批量生成分子的2D结构图和3D结构图。直接生成图片文件到当前目录。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "molecules": {
                "type": "object",
                "description": "分子字典，键为分子名称，值为SMILES字符串。例如: {'ethanol': 'CCO', 'benzene': 'c1ccccc1'}"
              }
            },
            "required": [
              "molecules"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_visualize.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "optimize_geometry",
          "description": "对分子进行3D几何优化，使用力场方法最小化能量。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串"
              },
              "method": {
                "type": "string",
                "description": "3D坐标生成方法",
                "enum": [
                  "ETKDGv3",
                  "ETKDG",
                  "KDG",
                  "distance_geometry"
                ]
              },
              "force_field": {
                "type": "string",
                "description": "力场类型，MMFF（Merck分子力场）或UFF（通用力场）",
                "enum": [
                  "MMFF",
                  "UFF"
                ]
              },
              "max_iters": {
                "type": "integer",
                "description": "最大优化迭代次数，默认200"
              }
            },
            "required": [
              "smiles",
              "method"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_analyzer.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "get_3d_properties",
          "description": "计算分子的3D性质，包括主惯性矩、形状描述符、回转半径等。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串"
              },
              "method": {
                "type": "string",
                "description": "3D坐标生成方法",
                "enum": [
                  "ETKDGv3",
                  "ETKDG",
                  "KDG"
                ]
              },
              "conf_id": {
                "type": "integer",
                "description": "构象ID，默认为0（第一个构象）"
              }
            },
            "required": [
              "smiles",
              "method"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_analyzer.py"
        }
      }
    ],
    "refined_version_data": {
      "refined_question": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。",
      "final_answer": {
        "(1)": {
          "MW": 246.2,
          "logP": -0.9,
          "TPSA": 92.0,
          "HBD": 3,
          "HBA": 5,
          "RB": 4,
          "Lipinski_violations_eval_1": 0,
          "Lipinski_violations_eval_2": 0,
          "result_relation": "两次结果相同（均满足规则）"
        },
        "(2)": {
          "optimization_method": "ETKDG",
          "force_field": "MMFF",
          "max_iterations": 500,
          "converged": true,
          "total_energy": "72.8 kcal/mol",
          "Rg": 2.35,
          "PMI": [
            120.4,
            230.8,
            350.9
          ],
          "asphericity": 0.24,
          "eccentricity": 0.78
        },
        "(3)": {
          "SAS_raw": 4.7,
          "SAS_final_1dp": 4.7,
          "source": "题面给定SAS_raw",
          "range_check": "[1,10]内"
        },
        "(4)": {
          "path_2D": "/images/Floxuridine_2D.png",
          "path_3D": "/models/Floxuridine_3D.sdf",
          "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
        },
        "(5)": {
          "summary_index": {
            "P1": "(1)中的理化性质与Lipinski评估结果",
            "G1": "(2)中的几何优化与形状描述符",
            "S1": "(3)中的最终SAS",
            "Paths": "(4)中的2D/3D路径"
          },
          "cross_checks": [
            "SAS范围：S1∈[1,10]",
            "Lipinski两次评估结果相同，均满足规则",
            "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
          ],
          "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
        }
      }
    },
    "metadata_summary": {
      "subject": "化学",
      "topic": "药物化学与合成可及性",
      "test_type": "refined",
      "original_question_id": "42",
      "subject_topic_key": "化学::药物化学与合成可及性"
    }
  },
  "model": "gemini-2.5-pro",
  "use_tools": false,
  "mode": "text_mode",
  "rounds": 1,
  "messages": [
    {
      "role": "user",
      "content": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。"
    },
    {
      "role": "assistant",
      "content": "好的，根据您提供的Floxuridine分子数据，我将按要求进行分析和报告。\n\n---\n\n### Floxuridine (5-氟脱氧尿苷) 分子性质报告\n\n#### (1) Lipinski五规则评估\n\n*   **理化性质报告:**\n    *   MW = 246.2\n    *   logP = -0.9\n    *   TPSA = 92.0 Å²\n    *   HBD = 3\n    *   HBA = 5\n    *   RB = 4\n\n*   **第一次独立评估 (Lipinski五规则):**\n    *   MW = 246.2 (≤ 500), **通过**\n    *   logP = -0.9 (≤ 5), **通过**\n    *   HBD = 3 (≤ 5), **通过**\n    *   HBA = 5 (≤ 10), **通过**\n    *   **违例数: 0**\n\n*   **第二次独立评估 (Lipinski五规则):**\n    *   MW = 246.2 (≤ 500), **通过**\n    *   logP = -0.9 (≤ 5), **通过**\n    *   HBD = 3 (≤ 5), **通过**\n    *   HBA = 5 (≤ 10), **通过**\n    *   **违例数: 0**\n\n两次独立评估的结果**相同**，均为0个违例。\n\n#### (2) 3D几何优化与形状描述符\n\n*   **3D几何优化参数:**\n    *   方法: ETKDG\n    *   力场: MMFF\n    *   最大迭代: 500\n    *   收敛: true\n    *   总能量: 72.8 kcal/mol\n\n*   **3D形状描述符:**\n    *   Rg = 2.35\n    *   PMI = [120.4, 230.8, 350.9]\n    *   asphericity = 0.24\n    *   eccentricity = 0.78\n\n#### (3) 合成可及性分数 (SAS)\n\n*   **最终SAS分数: 4.7**\n*   **说明:** 来源为题面给定的SAS_raw=4.7，按四舍五入保留1位小数后为4.7。该值已进行[1,10]范围检查，4.7在此有效范围内。\n\n#### (4) 2D/3D结构图\n\n*   **2D结构图路径:** \"/images/Floxuridine_2D.png\"\n*   **3D结构图路径:** \"/models/Floxuridine_3D.sdf\"\n*   **说明:** 上述路径指向的2D和3D结构图可用于直观核对嘧啶环5位的氟原子取代以及脱氧核糖环上的手性中心（相对构型）是否与SMILES字符串描述一致。\n\n#### (5) 汇总、交叉校验与结论\n\n*   **数值汇总清单:**\n| 参数 | 数值 | 单位 |\n| :--- | :--- | :--- |\n| **理化性质** | | |\n| MW | 246.2 | |\n| logP | -0.9 | |\n| TPSA | 92.0 | Å² |\n| HBD | 3 | |\n| HBA | 5 | |\n| RB | 4 | |\n| **3D几何/形状** | | |\n| 总能量 | 72.8 | kcal/mol |\n| Rg | 2.35 | |\n| asphericity | 0.24 | |\n| eccentricity | 0.78 | |\n| **成药性/合成** | | |\n| Lipinski违例数 | 0 | |\n| SAS | 4.7 | |\n\n*   **交叉校验清单:**\n    *   **SAS范围检查:** SAS=4.7，在[1,10]的合理范围内，校验通过。\n    *   **理化属性重复评估:** 两次独立的Lipinski五规则评估结果完全相同（均为0个违例），校验通过。\n    *   **形状与理化属性的合理性:**\n        *   **理化属性:** logP=-0.9，TPSA=92.0 Å²，表明分子具有高极性和亲水性，这与分子结构中含有糖环和多个羟基/酰胺基团的特征相符。\n        *   **形状属性:** Rg=2.35，asphericity=0.24，eccentricity=0.78，描述了一个紧凑但非球形的分子构象，这与由一个平面杂环（嘧啶）和一个非平面环（糖环）组成的核苷类似物结构相符。\n\n*   **总体成药性结论:**\n    该分子完全符合Lipinski五规则（0个违例），且TPSA（92.0 Å²）和RB（4）等参数均在类药分子的理想范围内，表明其具有良好的类药性和潜在的口服生物利用度。\n*   **最终SAS:**\n    **4.7**"
    },
    {
      "role": "user",
      "content": "现在请仅输出严格 JSON，必须完全匹配以下结构（键名、层级、字段齐全），所有数值用数字表示（保留2-3位小数），布尔用 true/false，字符串填写说明文字。不要输出任何解释文字或前后缀，也不要多余字段；若无法计算某值请给出可解析的近似值。\n\n{\n  \"(1)\": {\n    \"MW\": \"[数值]\",\n    \"logP\": \"[数值]\",\n    \"TPSA\": \"[数值]\",\n    \"HBD\": \"[数值]\",\n    \"HBA\": \"[数值]\",\n    \"RB\": \"[数值]\",\n    \"Lipinski_violations_eval_1\": \"[数值]\",\n    \"Lipinski_violations_eval_2\": \"[数值]\",\n    \"result_relation\": \"[字符串]\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"[字符串]\",\n    \"force_field\": \"[字符串]\",\n    \"max_iterations\": \"[数值]\",\n    \"converged\": \"[布尔值]\",\n    \"total_energy\": \"[字符串]\",\n    \"Rg\": \"[数值]\",\n    \"PMI\": \"[3个数值的数组]\",\n    \"asphericity\": \"[数值]\",\n    \"eccentricity\": \"[数值]\"\n  },\n  \"(3)\": {\n    \"SAS_raw\": \"[数值]\",\n    \"SAS_final_1dp\": \"[数值]\",\n    \"source\": \"[字符串]\",\n    \"range_check\": \"[字符串]\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"[字符串]\",\n    \"path_3D\": \"[字符串]\",\n    \"usage\": \"[字符串]\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"[字符串]\",\n      \"G1\": \"[字符串]\",\n      \"S1\": \"[字符串]\",\n      \"Paths\": \"[字符串]\"\n    },\n    \"cross_checks\": \"[3个字符串的数组]\",\n    \"overall_conclusion\": \"[字符串]\"\n  }\n}"
    },
    {
      "role": "assistant",
      "content": "```json\n{\n  \"(1)\": {\n    \"MW\": 246.2,\n    \"logP\": -0.9,\n    \"TPSA\": 92.0,\n    \"HBD\": 3,\n    \"HBA\": 5,\n    \"RB\": 4,\n    \"Lipinski_violations_eval_1\": 0,\n    \"Lipinski_violations_eval_2\": 0,\n    \"result_relation\": \"两次独立评估结果相同\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500,\n    \"converged\": true,\n    \"total_energy\": \"72.8 kcal/mol\",\n    \"Rg\": 2.35,\n    \"PMI\": [\n      120.4,\n      230.8,\n      350.9\n    ],\n    \"asphericity\": 0.24,\n    \"eccentricity\": 0.78\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.7,\n    \"SAS_final_1dp\": 4.7,\n    \"source\": \"题面给定\",\n    \"range_check\": \"SAS=4.7, 在[1,10]有效范围内\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"用于核对嘧啶5位氟取代与糖环手性（相对构型）\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"理化属性：MW=246.2, logP=-0.9, TPSA=92.0, HBD=3, HBA=5, RB=4\",\n      \"G1\": \"3D几何：Rg=2.35, asphericity=0.24, eccentricity=0.78\",\n      \"S1\": \"成药性/合成：Lipinski违例数=0, SAS=4.7\",\n      \"Paths\": \"2D/3D路径已提供\"\n    },\n    \"cross_checks\": [\n      \"SAS范围检查：SAS=4.7，在[1,10]内，通过。\",\n      \"理化属性重复评估：两次Lipinski评估结果相同（均为0违例），通过。\",\n      \"形状与理化属性合理性：高极性（logP, TPSA）与非球形核苷结构（asphericity, eccentricity）一致，通过。\"\n    ],\n    \"overall_conclusion\": \"分子完全符合Lipinski五规则，类药性良好，合成可及性中等（SAS=4.7）。\"\n  }\n}\n```"
    }
  ],
  "metadata": {
    "subject": "化学",
    "topic": "药物化学与合成可及性",
    "image_path": [],
    "solution_steps": [
      "【分子识别与解析】解析5-Fluorodeoxyuridine的SMILES字符串：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O",
      "【SAS计算】调用 calculate_synthetic_accessibility(smiles) 使用Ertl-Schuffenhauer算法计算合成可及性分数",
      "SAS基于分子复杂度、环系统、立体化学和已知合成片段进行统计评估",
      "获得SAS = 3.5，对应\"相对容易合成\"（2.0-4.0范围）",
      "【理化性质分析】调用 mol_basic_physicochemical_info(smiles) 获取完整的分子信息",
      "分子式：C9H11FN2O5，分子量：246.07 g/mol",
      "LogP = -1.68（亲水性强），TPSA = 104.55 Å²（极性表面积大）",
      "氢键供体：3，氢键受体：6，可旋转键：2",
      "芳香环：1（嘧啶环），总环数：2（嘧啶环+糖环）",
      "【Lipinski成药性评估】检查Lipinski五规则的违规情况",
      "✓ MW(246.07) ≤ 500，✓ LogP(-1.68) ≤ 5，✓ HBD(3) ≤ 5，✓ HBA(6) ≤ 10",
      "违规数 = 0，类药性 = ✓ 是",
      "【3D可视化】调用 chem_visualizer 生成2D结构图和3D投影图",
      "生成图像：5_Fluorodeoxyuridine_2d.png（平面结构）",
      "5_Fluorodeoxyuridine_3d_projection.png（3D投影）",
      "5_Fluorodeoxyuridine_3d_matplotlib.png（3D立体图）",
      "【3D结构优化】调用 optimize_geometry(smiles, method='ETKDGv3', force_field='MMFF', max_iters=200)",
      "初始能量：-0.55 kcal/mol → 优化后能量：-30.79 kcal/mol",
      "能量降低：ΔE = -30.24 kcal/mol（结构显著稳定化）",
      "【3D性质计算】调用 get_3d_properties(smiles, method='ETKDGv3', conf_id=0)",
      "主惯性矩：PMI1=496.58, PMI2=2099.67, PMI3=2215.85 amu·Ų",
      "归一化惯性矩比：NPR1=0.224, NPR2=0.948",
      "分子形状：极端棒状/纤维状（NPR1<0.5, NPR2>0.95）",
      "回转半径：Rg = 3.126 Å（分子尺寸的特征长度）",
      "非球形度：asphericity = 0.478（显著偏离球形）",
      "偏心率：eccentricity = 0.975（高度拉伸的椭球形）",
      "【合成难度评估】根据SAS=3.5给出合成难度评价",
      "合成难度：相对容易合成（★★☆☆☆）",
      "核苷类似物的典型复杂度，适合药物开发",
      "【药物应用背景】5-FdU是胸苷酸合成酶抑制剂，用于治疗结直肠癌和肝癌",
      "商品名：Floxuridine, FUDR",
      "作用机制：干扰DNA合成，诱导癌细胞凋亡",
      "【最终答案】合成可及性分数 SAS = 3.5"
    ],
    "tool_expected": [
      "calculate_synthetic_accessibility",
      "mol_basic_physicochemical_info",
      "chem_visualizer",
      "optimize_geometry",
      "get_3d_properties"
    ],
    "golden_answer": [
      {
        "(1)": {
          "MW": 246.2,
          "logP": -0.9,
          "TPSA": 92.0,
          "HBD": 3,
          "HBA": 5,
          "RB": 4,
          "Lipinski_violations_eval_1": 0,
          "Lipinski_violations_eval_2": 0,
          "result_relation": "两次结果相同（均满足规则）"
        },
        "(2)": {
          "optimization_method": "ETKDG",
          "force_field": "MMFF",
          "max_iterations": 500,
          "converged": true,
          "total_energy": "72.8 kcal/mol",
          "Rg": 2.35,
          "PMI": [
            120.4,
            230.8,
            350.9
          ],
          "asphericity": 0.24,
          "eccentricity": 0.78
        },
        "(3)": {
          "SAS_raw": 4.7,
          "SAS_final_1dp": 4.7,
          "source": "题面给定SAS_raw",
          "range_check": "[1,10]内"
        },
        "(4)": {
          "path_2D": "/images/Floxuridine_2D.png",
          "path_3D": "/models/Floxuridine_3D.sdf",
          "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
        },
        "(5)": {
          "summary_index": {
            "P1": "(1)中的理化性质与Lipinski评估结果",
            "G1": "(2)中的几何优化与形状描述符",
            "S1": "(3)中的最终SAS",
            "Paths": "(4)中的2D/3D路径"
          },
          "cross_checks": [
            "SAS范围：S1∈[1,10]",
            "Lipinski两次评估结果相同，均满足规则",
            "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
          ],
          "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
        }
      }
    ],
    "original_question_id": "42",
    "test_type": "refined"
  },
  "metadata_summary": {
    "subject": "化学",
    "topic": "药物化学与合成可及性",
    "test_type": "refined",
    "original_question_id": "42",
    "subject_topic_key": "化学::药物化学与合成可及性"
  },
  "answer_template": {
    "(1)": {
      "MW": "[数值]",
      "logP": "[数值]",
      "TPSA": "[数值]",
      "HBD": "[数值]",
      "HBA": "[数值]",
      "RB": "[数值]",
      "Lipinski_violations_eval_1": "[数值]",
      "Lipinski_violations_eval_2": "[数值]",
      "result_relation": "[字符串]"
    },
    "(2)": {
      "optimization_method": "[字符串]",
      "force_field": "[字符串]",
      "max_iterations": "[数值]",
      "converged": "[布尔值]",
      "total_energy": "[字符串]",
      "Rg": "[数值]",
      "PMI": "[3个数值的数组]",
      "asphericity": "[数值]",
      "eccentricity": "[数值]"
    },
    "(3)": {
      "SAS_raw": "[数值]",
      "SAS_final_1dp": "[数值]",
      "source": "[字符串]",
      "range_check": "[字符串]"
    },
    "(4)": {
      "path_2D": "[字符串]",
      "path_3D": "[字符串]",
      "usage": "[字符串]"
    },
    "(5)": {
      "summary_index": {
        "P1": "[字符串]",
        "G1": "[字符串]",
        "S1": "[字符串]",
        "Paths": "[字符串]"
      },
      "cross_checks": "[3个字符串的数组]",
      "overall_conclusion": "[字符串]"
    }
  },
  "golden_standard": {
    "(1)": {
      "MW": 246.2,
      "logP": -0.9,
      "TPSA": 92.0,
      "HBD": 3,
      "HBA": 5,
      "RB": 4,
      "Lipinski_violations_eval_1": 0,
      "Lipinski_violations_eval_2": 0,
      "result_relation": "两次结果相同（均满足规则）"
    },
    "(2)": {
      "optimization_method": "ETKDG",
      "force_field": "MMFF",
      "max_iterations": 500,
      "converged": true,
      "total_energy": "72.8 kcal/mol",
      "Rg": 2.35,
      "PMI": [
        120.4,
        230.8,
        350.9
      ],
      "asphericity": 0.24,
      "eccentricity": 0.78
    },
    "(3)": {
      "SAS_raw": 4.7,
      "SAS_final_1dp": 4.7,
      "source": "题面给定SAS_raw",
      "range_check": "[1,10]内"
    },
    "(4)": {
      "path_2D": "/images/Floxuridine_2D.png",
      "path_3D": "/models/Floxuridine_3D.sdf",
      "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
    },
    "(5)": {
      "summary_index": {
        "P1": "(1)中的理化性质与Lipinski评估结果",
        "G1": "(2)中的几何优化与形状描述符",
        "S1": "(3)中的最终SAS",
        "Paths": "(4)中的2D/3D路径"
      },
      "cross_checks": [
        "SAS范围：S1∈[1,10]",
        "Lipinski两次评估结果相同，均满足规则",
        "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
      ],
      "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
    }
  },
  "expected_format": "structured_json",
  "model_structured_answer": {
    "(1)": {
      "MW": 246.2,
      "logP": -0.9,
      "TPSA": 92.0,
      "HBD": 3,
      "HBA": 5,
      "RB": 4,
      "Lipinski_violations_eval_1": 0,
      "Lipinski_violations_eval_2": 0,
      "result_relation": "两次独立评估结果相同"
    },
    "(2)": {
      "optimization_method": "ETKDG",
      "force_field": "MMFF",
      "max_iterations": 500,
      "converged": true,
      "total_energy": "72.8 kcal/mol",
      "Rg": 2.35,
      "PMI": [
        120.4,
        230.8,
        350.9
      ],
      "asphericity": 0.24,
      "eccentricity": 0.78
    },
    "(3)": {
      "SAS_raw": 4.7,
      "SAS_final_1dp": 4.7,
      "source": "题面给定",
      "range_check": "SAS=4.7, 在[1,10]有效范围内"
    },
    "(4)": {
      "path_2D": "/images/Floxuridine_2D.png",
      "path_3D": "/models/Floxuridine_3D.sdf",
      "usage": "用于核对嘧啶5位氟取代与糖环手性（相对构型）"
    },
    "(5)": {
      "summary_index": {
        "P1": "理化属性：MW=246.2, logP=-0.9, TPSA=92.0, HBD=3, HBA=5, RB=4",
        "G1": "3D几何：Rg=2.35, asphericity=0.24, eccentricity=0.78",
        "S1": "成药性/合成：Lipinski违例数=0, SAS=4.7",
        "Paths": "2D/3D路径已提供"
      },
      "cross_checks": [
        "SAS范围检查：SAS=4.7，在[1,10]内，通过。",
        "理化属性重复评估：两次Lipinski评估结果相同（均为0违例），通过。",
        "形状与理化属性合理性：高极性（logP, TPSA）与非球形核苷结构（asphericity, eccentricity）一致，通过。"
      ],
      "overall_conclusion": "分子完全符合Lipinski五规则，类药性良好，合成可及性中等（SAS=4.7）。"
    }
  },
  "answer_extraction_success": true,
  "model_raw_answer": "```json\n{\n  \"(1)\": {\n    \"MW\": 246.2,\n    \"logP\": -0.9,\n    \"TPSA\": 92.0,\n    \"HBD\": 3,\n    \"HBA\": 5,\n    \"RB\": 4,\n    \"Lipinski_violations_eval_1\": 0,\n    \"Lipinski_violations_eval_2\": 0,\n    \"result_relation\": \"两次独立评估结果相同\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500,\n    \"converged\": true,\n    \"total_energy\": \"72.8 kcal/mol\",\n    \"Rg\": 2.35,\n    \"PMI\": [\n      120.4,\n      230.8,\n      350.9\n    ],\n    \"asphericity\": 0.24,\n    \"eccentricity\": 0.78\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.7,\n    \"SAS_final_1dp\": 4.7,\n    \"source\": \"题面给定\",\n    \"range_check\": \"SAS=4.7, 在[1,10]有效范围内\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"用于核对嘧啶5位氟取代与糖环手性（相对构型）\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"理化属性：MW=246.2, logP=-0.9, TPSA=92.0, HBD=3, HBA=5, RB=4\",\n      \"G1\": \"3D几何：Rg=2.35, asphericity=0.24, eccentricity=0.78\",\n      \"S1\": \"成药性/合成：Lipinski违例数=0, SAS=4.7\",\n      \"Paths\": \"2D/3D路径已提供\"\n    },\n    \"cross_checks\": [\n      \"SAS范围检查：SAS=4.7，在[1,10]内，通过。\",\n      \"理化属性重复评估：两次Lipinski评估结果相同（均为0违例），通过。\",\n      \"形状与理化属性合理性：高极性（logP, TPSA）与非球形核苷结构（asphericity, eccentricity）一致，通过。\"\n    ],\n    \"overall_conclusion\": \"分子完全符合Lipinski五规则，类药性良好，合成可及性中等（SAS=4.7）。\"\n  }\n}\n```",
  "model_last_assistant_message": {
    "role": "assistant",
    "content": "```json\n{\n  \"(1)\": {\n    \"MW\": 246.2,\n    \"logP\": -0.9,\n    \"TPSA\": 92.0,\n    \"HBD\": 3,\n    \"HBA\": 5,\n    \"RB\": 4,\n    \"Lipinski_violations_eval_1\": 0,\n    \"Lipinski_violations_eval_2\": 0,\n    \"result_relation\": \"两次独立评估结果相同\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500,\n    \"converged\": true,\n    \"total_energy\": \"72.8 kcal/mol\",\n    \"Rg\": 2.35,\n    \"PMI\": [\n      120.4,\n      230.8,\n      350.9\n    ],\n    \"asphericity\": 0.24,\n    \"eccentricity\": 0.78\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.7,\n    \"SAS_final_1dp\": 4.7,\n    \"source\": \"题面给定\",\n    \"range_check\": \"SAS=4.7, 在[1,10]有效范围内\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"用于核对嘧啶5位氟取代与糖环手性（相对构型）\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"理化属性：MW=246.2, logP=-0.9, TPSA=92.0, HBD=3, HBA=5, RB=4\",\n      \"G1\": \"3D几何：Rg=2.35, asphericity=0.24, eccentricity=0.78\",\n      \"S1\": \"成药性/合成：Lipinski违例数=0, SAS=4.7\",\n      \"Paths\": \"2D/3D路径已提供\"\n    },\n    \"cross_checks\": [\n      \"SAS范围检查：SAS=4.7，在[1,10]内，通过。\",\n      \"理化属性重复评估：两次Lipinski评估结果相同（均为0违例），通过。\",\n      \"形状与理化属性合理性：高极性（logP, TPSA）与非球形核苷结构（asphericity, eccentricity）一致，通过。\"\n    ],\n    \"overall_conclusion\": \"分子完全符合Lipinski五规则，类药性良好，合成可及性中等（SAS=4.7）。\"\n  }\n}\n```"
  },
  "evaluation_score": 0.9142857142857143,
  "evaluation_summary": "匹配字段: 32/35 (得分: 91.43%)",
  "evaluation_details": {
    "(1).MW": {
      "path": "(1).MW",
      "expected": 246.2,
      "actual": 246.2,
      "expected_num": 246.2,
      "actual_num": 246.2,
      "status": "match",
      "match_type": "exact"
    },
    "(1).logP": {
      "path": "(1).logP",
      "expected": -0.9,
      "actual": -0.9,
      "expected_num": -0.9,
      "actual_num": -0.9,
      "status": "match",
      "match_type": "exact"
    },
    "(1).TPSA": {
      "path": "(1).TPSA",
      "expected": 92.0,
      "actual": 92.0,
      "expected_num": 92.0,
      "actual_num": 92.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).HBD": {
      "path": "(1).HBD",
      "expected": 3,
      "actual": 3,
      "expected_num": 3.0,
      "actual_num": 3.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).HBA": {
      "path": "(1).HBA",
      "expected": 5,
      "actual": 5,
      "expected_num": 5.0,
      "actual_num": 5.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).RB": {
      "path": "(1).RB",
      "expected": 4,
      "actual": 4,
      "expected_num": 4.0,
      "actual_num": 4.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).Lipinski_violations_eval_1": {
      "path": "(1).Lipinski_violations_eval_1",
      "expected": 0,
      "actual": 0,
      "expected_num": 0.0,
      "actual_num": 0.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).Lipinski_violations_eval_2": {
      "path": "(1).Lipinski_violations_eval_2",
      "expected": 0,
      "actual": 0,
      "expected_num": 0.0,
      "actual_num": 0.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).result_relation": {
      "path": "(1).result_relation",
      "expected": "两次结果相同（均满足规则）",
      "actual": "两次独立评估结果相同",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(2).optimization_method": {
      "path": "(2).optimization_method",
      "expected": "ETKDG",
      "actual": "ETKDG",
      "status": "match",
      "match_type": "exact"
    },
    "(2).force_field": {
      "path": "(2).force_field",
      "expected": "MMFF",
      "actual": "MMFF",
      "status": "match",
      "match_type": "exact"
    },
    "(2).max_iterations": {
      "path": "(2).max_iterations",
      "expected": 500,
      "actual": 500,
      "expected_num": 500.0,
      "actual_num": 500.0,
      "status": "match",
      "match_type": "exact"
    },
    "(2).converged": {
      "path": "(2).converged",
      "expected": true,
      "actual": true,
      "expected_num": 1.0,
      "actual_num": 1.0,
      "status": "match",
      "match_type": "exact"
    },
    "(2).total_energy": {
      "path": "(2).total_energy",
      "expected": "72.8 kcal/mol",
      "actual": "72.8 kcal/mol",
      "status": "match",
      "match_type": "exact"
    },
    "(2).Rg": {
      "path": "(2).Rg",
      "expected": 2.35,
      "actual": 2.35,
      "expected_num": 2.35,
      "actual_num": 2.35,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[0]": {
      "path": "(2).PMI[0]",
      "expected": 120.4,
      "actual": 120.4,
      "expected_num": 120.4,
      "actual_num": 120.4,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[1]": {
      "path": "(2).PMI[1]",
      "expected": 230.8,
      "actual": 230.8,
      "expected_num": 230.8,
      "actual_num": 230.8,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[2]": {
      "path": "(2).PMI[2]",
      "expected": 350.9,
      "actual": 350.9,
      "expected_num": 350.9,
      "actual_num": 350.9,
      "status": "match",
      "match_type": "exact"
    },
    "(2).asphericity": {
      "path": "(2).asphericity",
      "expected": 0.24,
      "actual": 0.24,
      "expected_num": 0.24,
      "actual_num": 0.24,
      "status": "match",
      "match_type": "exact"
    },
    "(2).eccentricity": {
      "path": "(2).eccentricity",
      "expected": 0.78,
      "actual": 0.78,
      "expected_num": 0.78,
      "actual_num": 0.78,
      "status": "match",
      "match_type": "exact"
    },
    "(3).SAS_raw": {
      "path": "(3).SAS_raw",
      "expected": 4.7,
      "actual": 4.7,
      "expected_num": 4.7,
      "actual_num": 4.7,
      "status": "match",
      "match_type": "exact"
    },
    "(3).SAS_final_1dp": {
      "path": "(3).SAS_final_1dp",
      "expected": 4.7,
      "actual": 4.7,
      "expected_num": 4.7,
      "actual_num": 4.7,
      "status": "match",
      "match_type": "exact"
    },
    "(3).source": {
      "path": "(3).source",
      "expected": "题面给定SAS_raw",
      "actual": "题面给定",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(3).range_check": {
      "path": "(3).range_check",
      "expected": "[1,10]内",
      "actual": "SAS=4.7, 在[1,10]有效范围内",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(4).path_2D": {
      "path": "(4).path_2D",
      "expected": "/images/Floxuridine_2D.png",
      "actual": "/images/Floxuridine_2D.png",
      "status": "match",
      "match_type": "exact"
    },
    "(4).path_3D": {
      "path": "(4).path_3D",
      "expected": "/models/Floxuridine_3D.sdf",
      "actual": "/models/Floxuridine_3D.sdf",
      "status": "match",
      "match_type": "exact"
    },
    "(4).usage": {
      "path": "(4).usage",
      "expected": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性",
      "actual": "用于核对嘧啶5位氟取代与糖环手性（相对构型）",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.P1": {
      "path": "(5).summary_index.P1",
      "expected": "(1)中的理化性质与Lipinski评估结果",
      "actual": "理化属性：MW=246.2, logP=-0.9, TPSA=92.0, HBD=3, HBA=5, RB=4",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(5).summary_index.G1": {
      "path": "(5).summary_index.G1",
      "expected": "(2)中的几何优化与形状描述符",
      "actual": "3D几何：Rg=2.35, asphericity=0.24, eccentricity=0.78",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(5).summary_index.S1": {
      "path": "(5).summary_index.S1",
      "expected": "(3)中的最终SAS",
      "actual": "成药性/合成：Lipinski违例数=0, SAS=4.7",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.Paths": {
      "path": "(5).summary_index.Paths",
      "expected": "(4)中的2D/3D路径",
      "actual": "2D/3D路径已提供",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).cross_checks[0]": {
      "path": "(5).cross_checks[0]",
      "expected": "SAS范围：S1∈[1,10]",
      "actual": "SAS范围检查：SAS=4.7，在[1,10]内，通过。",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).cross_checks[1]": {
      "path": "(5).cross_checks[1]",
      "expected": "Lipinski两次评估结果相同，均满足规则",
      "actual": "理化属性重复评估：两次Lipinski评估结果相同（均为0违例），通过。",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).cross_checks[2]": {
      "path": "(5).cross_checks[2]",
      "expected": "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征",
      "actual": "形状与理化属性合理性：高极性（logP, TPSA）与非球形核苷结构（asphericity, eccentricity）一致，通过。",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).overall_conclusion": {
      "path": "(5).overall_conclusion",
      "expected": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征",
      "actual": "分子完全符合Lipinski五规则，类药性良好，合成可及性中等（SAS=4.7）。",
      "status": "match",
      "match_type": "secondary_llm_verification"
    }
  },
  "mode_folder": "without_tools",
  "evaluation_score_segments": {
    "0_25": 1.0,
    "0_50": 1.0,
    "0_75": 0.9629629629629629,
    "0_100": 0.9142857142857143
  }
}